# Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer

> **NCT04419181** · PHASE2 · WITHDRAWN · sponsor: **University of Rochester**

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Carboplatin
- **DRUG:** Trastuzumab
- **DRUG:** Pertuzumab
- **DRUG:** Trastuzumab emtansine

## Key facts

- **NCT ID:** NCT04419181
- **Lead sponsor:** University of Rochester
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-08-11
- **Primary completion:** 2026-06-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Change in the landscape of current treatment of early stage breast cancer. Larger clinical trials answering similar questions are expected to result in the next few years.
- **Last updated:** 2025-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04419181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04419181, "Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04419181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*